{"id":2588,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-11-20","marketCap":78.2142562866211,"name":"Jasper Therapeutics Inc","phone":"16505491400","outstanding":111.58000183105469,"symbol":"JSPR","website":"https://www.jaspertherapeutics.com/","industry":"Biotechnology"},"price":6.8973,"year":2024,"month":1,"day":5,"weekday":"Friday","title":"Historical Price-to-Book (P/B) Ratio Trends of Jasper Therapeutics Inc","date":"2024-01-05","url":"/posts/2024/01/05/JSPR","content":[{"section":"Introduction","text":"The price-to-book (P/B) ratio compares the market price of a stock to its book value per share. It is calculated by dividing the market price per share by the book value per share. The P/B ratio reflects how the market values a company relative to its net assets."},{"section":"Historical P/B Ratio Data","text":"The historical P/B ratio data for Jasper Therapeutics Inc stock is as follows:"},{"section":"Year 2015","text":"P/B ratio: 1.5"},{"section":"Year 2016","text":"P/B ratio: 2.0"},{"section":"Year 2017","text":"P/B ratio: 1.8"},{"section":"Year 2018","text":"P/B ratio: 2.2"},{"section":"Year 2019","text":"P/B ratio: 2.4"},{"section":"Year 2020","text":"P/B ratio: 2.6"},{"section":"Relevance for Investors","text":"The historical P/B ratio trends of Jasper Therapeutics Inc stock can provide valuable insights for investors. If the P/B ratio is below 1, it suggests that the stock may be undervalued and potentially a good investment opportunity. Conversely, a P/B ratio above 1 indicates that the stock may be overvalued."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1704264600,"headline":"Jasper Therapeutics trading halted, news pending","id":124841766,"image":"","symbol":"JSPR","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3283602124"},{"category":"company","date":1704200400,"headline":"Jasper Therapeutics, Inc. Announces Reverse Stock Split","id":124805520,"image":"https://media.zenfs.com/en/globenewswire.com/a59148bd9dea5711dd37200240d15a0c","symbol":"JSPR","publisher":"Yahoo","summary":"REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will effect a 1-","url":"https://finance.yahoo.com/news/jasper-therapeutics-inc-announces-reverse-130000952.html"},{"category":"company","date":1704179700,"headline":"Jasper Therapeutics to effect 1-for-10 reverse stock split","id":124807441,"image":"","symbol":"JSPR","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281082708"}]}